EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient

Gerardo Uriel Viquez Burboa, Miguel Ángel Rafael Flores Guillén

Skin Appendage Disorders · 16.05.2026 · 1-7

DOI: 10.1159/000552598 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Skin Appendage Disorders, online erschienen am 16.05.2026. Verfasst von Gerardo Uriel Viquez Burboa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Medicina Interna/Dermatología, Hospital General Regional No. 2 "Guillermo Fajardo Ortiz," IMSS, Profesor de Dermatología, UNAM e IPN,…. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a disproportionately high burden of metabolic comorbidities, including obesity, metabolic syndrome, type 2 diabetes mellitus (T2DM), dyslipidaemia, and polycystic ovary syndrome. Despite this, clinical management of HS has historically remained siloed within dermatology, with insufficient integration of cardiometabolic risk management. Summary: GLP-1 receptor agonists (GLP-1 RAs) – a drug class now established for T2DM, obesity, and cardiovascular risk reduction – have recently emerged as candidate agents for HS. A systematic review published in 2024 and two pivotal real-world studies published in 2025 provide preliminary evidence that GLP-1 RAs improve HS disease activity through both weight loss and direct anti-inflammatory mechanisms. We argue that this evidence base is already sufficient to justify a paradigm shift: GLP-1 RAs should be considered as adjunctive components of a multidisciplinary treatment strategy for HS patients with concurrent cardiometabolic disease. We propose a practical clinical framework for patient selection and monitoring and call for dedicated randomised controlled trials. Key Messages: Metabolic comorbidities are mechanistically linked to HS pathogenesis and are inadequately addressed in current clinical practice. GLP-1 RAs offer dual benefit in HS – improving both metabolic outcomes and HS disease activity. Dermatologists should screen every HS patient for cardiometabolic comorbidities and advocate for GLP-1 RA therapy in eligible patients as part of a multidisciplinary approach.

Schlagwörter

Stichwörter der Autor:innen

Clinical perspectiveGLP-1 receptor agonistsHidradenitis suppurativaLiraglutideMetabolic syndromeMultidisciplinary managementObesitySemaglutideType 2 diabetesUnmet needs

Autor:innen und Institutionen

  • Departamento de Medicina Interna/Dermatología, Hospital General Regional No. 2 "Guillermo Fajardo Ortiz," IMSS, Profesor de Dermatología, UNAM e IPN, Mexico City, Mexico.
  • Departamento de Salud Digital, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM, Mexico City, Mexico.

Zitieren

APA

Viquez Burboa, G. U., & Flores Guillén, M. Á. R. (2026). GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient. Skin Appendage Disorders, 1-7. https://doi.org/10.1159/000552598

Vancouver

Viquez Burboa GU, Flores Guillén MÁR. GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient. Skin Appendage Disorders. 2026:1-7. doi:10.1159/000552598

BibTeX
@article{ViquezBurboa2026,
  author = {Viquez Burboa, Gerardo Uriel and Flores Guillén, Miguel Ángel Rafael},
  title = {GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient},
  journal = {Skin Appendage Disorders},
  year = {2026},
  pages = {1--7},
  doi = {10.1159/000552598}
}
Kostenlos starten →